Thermo Fisher Scientific Other — Consolidated long-lived assets increased by 20.1% to $5.47B in Q4 2025 compared to the prior quarter.
An increase indicates significant capital investment or asset acquisition in non-core segments, whereas a decrease may signal asset impairment, depreciation, or a reduction in the scale of these operations.
This metric measures the total book value of long-term, non-current assets, such as property, plant, equipment, and inta...
Comparable to 'Other' or 'Unallocated' long-lived assets reported by diversified industrial or life science peers, reflecting the footprint of non-core business segments.
tmo_segment_other_consolidated_long_lived_assets| Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|
| Value | $4.65B | $4.55B | $5.47B |
| QoQ Change | — | -2.2% | +20.1% |
| YoY Change | — | -2.2% | +20.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.